TVTX Institutional Ownership

TRAVERE THERAPEUTICS INC

Latest close $62.76 as of Aug 5, 2026

Create account to watch
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices. Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes. Filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro. The overall institutional consensus preview remains public. Compare plans.
Cross-institution intelligence

Institutional Research

Each institution is compared with its own prior filing, then the latest institution-level directions are compared for breadth.

Latest filing Aug 6, 2026
Public consensus preview Broad accumulation 86/100 institutional research score
Multi-institution accumulation 5 tracked institutions Latest filing Aug 6, 2026

2 accumulating across 2 comparable institutions.

Accumulating2
Unchanged0
Reducing0
Exited0

The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.

Price context

52-week position is market context and does not change the institutional consensus score.

52-week low$14.36 52-week high$60.10
Latest close $62.76 100.0% through the range

Tracked institutions

Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.

Latest observation Jun 30, 2026
State Street Feb 9, 2026 filed
BlackRock Legacy Jan 24, 2024 filed
Fidelity / FMR Aug 6, 2026 filed
Vanguard Capital Management Apr 30, 2026 filed
Vanguard Group Mar 27, 2026 filed
Detailed institutional research

See what is driving the consensus.

Unlock holder-by-holder changes, ownership history, breadth by period, disclosure timing, and filing-specific signal analysis.

Create free account Compare Investor and Pro

A free account adds watchlists and reveals tracker research gauges. Investor or Pro unlocks the detailed research above.

Beneficial ownership filing history

Showing 3 of 7 parsed filing(s) · 4 older require more history access
Holder Observed / filed Reported change Shares Ownership Observation Filing Latest
Fidelity / FMR CIK0000315066 Jun 30, 2026 observed Aug 6, 2026 filed · 37d Schedule 13G amendment Earliest Schedule 13G amendment found 7.1K 7.70% $56.81 $64.44 $62.76
Vanguard Capital Management CIK0002100119 Mar 31, 2026 observed Apr 30, 2026 filed · 30d Initial Schedule 13G Initial Schedule 13G 4.7M 12.00% $29.71 $42.12 $62.76
Vanguard Group CIK0000102909 Mar 13, 2026 observed Mar 27, 2026 filed · 14d Schedule 13G amendment Earliest Schedule 13G amendment found 11 12.00% $27.80 $27.25 $62.76
Explore more institutional activity

Related research

Crawlable links to other securities with similar institutional consensus or recent multi-institution accumulation.

Similar research strength

OPFI OPPFI INC 86/100 Broad accumulation PHAT PHATHOM PHARMACEUTICALS INC 86/100 Broad accumulation AGX ARGAN INC 86/100 Broad accumulation SRPT Sarepta Therapeutics, Inc. 87/100 Broad accumulation

Recent multi-institution accumulation

PCVX VAXCYTE INC 2 accumulating Aug 6, 2026 VVX V2X INC 2 accumulating Aug 6, 2026 VSEC VSE CORP 3 accumulating Jul 31, 2026 RXRX RECURSION PHARMACEUTICALS-A 2 accumulating Jul 31, 2026